ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Clinical efficacy and safety of Cadonilimab immunotherapy in recurrent or metastatic gynecological malignancies: a retrospective study.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundCadonilimab is a novel PD-1/CTLA-4 bispecific antibody approved for cervical cancer treatment in China in 2022. We conducted a retrospective study to investigate the efficacy and safety of Cadonilimab in patients with recurrent or metastatic gynecological malignancies.
methodsWe retrospectively enrolled 27 patients with recurrent or metastatic gynecological malignancies, confirmed by pathology or cytology between July 2022 and February 2025. All patients received at least two cycles of Cadonilimab. The primary endpoints were objective response rate and disease control rate according to RECIST v1.1. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety.
resultsIn the enrolled population, the mPFS and mOS were 10.90 months (95% CI: 9.57-12.23) and 52.93 months (95% CI: 19.62-73.38), respectively. Among the first-line patients with advanced cervical cancer, ORR was 66.67% (10/15,95% CI, 41.71 to 84.82), DCR was 100.00% (15/15,95% CI 79.67 to 100.00), the mPFS and mOS were 15.9 months (95% CI: 7.72-24.08) and 46.5 months (95% CI: 19.62-73.38), respectively. There was no significant difference in PFS (P = 0.45, HR: 1.704, 95% CI: 0.38-7.70) and OS (P = 0.91, HR: 1.14, 95% CI: 0.11-11.46) between Cadonilimab-based chemotherapy with or without bevacizumab. In the responder population, 14 (51.85%) patients experienced at least one treatment-related adverse event (TRAE), only 1(3.70%) patient developed grade 3-4 adverse events. No treatment-related deaths occurred during the study.
conclusionCadonilimab-based chemotherapy with or without bevacizumab had a promising efficacy and manageable safety profile in the treatment of recurrent or metastatic gynecological malignancies.
Indexed as
Identifiers
41634266What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.